The estimated Net Worth of Scott Dnea Partners 14, L.P... is at least $622 mil dollars as of 27 March 2018. Mr P owns over 707,964 units of TRACON Pharmaceuticals Inc stock worth over $239,154 and over the last 7 years he sold TCON stock worth over $0. In addition, he makes $382,824 as Chief Financial Officer at TRACON Pharmaceuticals Inc.
Mr has made over 1 trades of the TRACON Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 707,964 units of TCON stock worth $1,911,503 on 27 March 2018.
The largest trade he's ever made was buying 707,964 units of TRACON Pharmaceuticals Inc stock on 27 March 2018 worth over $1,911,503. On average, Mr trades about 707,964 units every 0 days since 2018. As of 27 March 2018 he still owns at least 3,466,003 units of TRACON Pharmaceuticals Inc stock.
You can see the complete history of Mr P stock trades at the bottom of the page.
Scott B. Brown CPA, M.S. is the Chief Financial Officer at TRACON Pharmaceuticals Inc.
As the Chief Financial Officer of TRACON Pharmaceuticals Inc, the total compensation of Mr S at TRACON Pharmaceuticals Inc is $382,824. There are 5 executives at TRACON Pharmaceuticals Inc getting paid more, with Charles Theuer having the highest compensation of $1,085,320.
Mr S is 40, he's been the Chief Financial Officer of TRACON Pharmaceuticals Inc since . There are 13 older and no younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.
Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include: